Study guide

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers)

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers)

Key Takeaways Explain This Topic AI

CTS asthma diagnosis needs objective variable airflow limitation, such as an FEV1 rise of at least 12% and 200 mL after bronchodilator, or a methacholine PC20 below 4 mg/mL (4 to 16 borderline).

CTS 2021 control criteria include daytime symptoms and reliever use each no more than 2 per week, night symptoms under 1 per week, normal activity, no absences, and FEV1 or PEF at least 90% of best.

For mild asthma, CTS 2021 prefers daily low-dose ICS plus PRN SABA; PRN budesonide-formoterol is for patients 12 or older whose adherence to daily ICS stays poor despite support.

Moderate asthma steps up to low-dose ICS/LABA or budesonide-formoterol maintenance-and-reliever therapy, then to higher doses, add-on LAMA, LTRA, or phenotype-directed biologics.

Acute exacerbations need repeated salbutamol by pMDI and spacer with ipratropium when severe, early systemic corticosteroid (prednisone about 50 mg daily for 5 days), and oxygen to SaO2 93% to 95%.

Last updated: October 2026

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers)

Asthma is a chronic inflammatory disorder of the conducting airways characterized by bronchial hyperresponsiveness, tissue remodeling, mucosal edema, mucus hypersecretion, and variable, reversible airflow limitation. In Canada, asthma affects over 3.8 million children and adults, representing one of the most frequent respiratory conditions encountered in community and hospital pharmacy practice. The Canadian Thoracic Society (CTS) Asthma Clinical Practice Guidelines provide an evidence-based clinical framework emphasizing that asthma is fundamentally an inflammatory disease; effective management requires addressing underlying chronic airway inflammation rather than relying solely on acute bronchodilation.

Objective Diagnostic Criteria for Asthma

Clinical suspicion of asthma is raised by episodic respiratory symptoms—including wheezing, shortness of breath, chest tightness, and cough—that vary over time and in intensity, frequently worsening at night or in the early morning and triggered by viral respiratory tract infections, cold dry air, exercise, chemical irritants, or aeroallergens. However, physical examination and clinical history alone are insufficient for confirmation. The CTS mandates objective demonstration of variable, reversible airflow obstruction .

1. Spirometry with Bronchodilator Reversibility (First-Line Confirmation)

Spirometry is the definitive diagnostic modality for individuals aged 6 years and older. Baseline airflow limitation is defined by a reduced forced expiratory volume in 1 second to forced vital capacity ratio ( F E V 1 / F V C FEV_1/FVC FE V 1 ​ / F V C ):

Adults : F E V 1 / F V C FEV_1/FVC FE V 1 ​ / F V C below the lower limit of normal (LLN) from age-adjusted reference equations, roughly less than 0.75 0.75 0.75 to 0.80 0.80 0.80 . The fixed 0.70 0.70 0.70 cut-off is the COPD convention, not the CTS asthma criterion.

Children (6–17 years) : F E V 1 / F V C FEV_1/FVC FE V 1 ​ / F V C below the LLN, roughly less than 0.80 0.80 0.80 to 0.90 0.90 0.90 . CTS OBJECTIVE ASTHMA DIAGNOSTIC WORKFLOW

  • Patient with Recurrent Wheeze, Cough, Dyspnea
  • │
  • ▼
  • Baseline Spirometry (Pre-BD)
  • │
  • ┌────────────────────────┴────────────────────────┐
  • ▼ ▼
  • FEV1/FVC Reduced FEV1/FVC Normal
  • │ │
  • ▼ ▼
  • Administer 200-400 mcg Salbutamol Alternate Objective Assessment
  • Wait 15 minutes and repeat FEV1 (Choose one of below)
  • │ │
  • ┌──────────────┴──────────────┐ ┌────────────────┼────────────────┐
  • ▼ ▼ ▼ ▼ ▼
  • FEV1 increases FEV1 increases Methacholine Peak Expiratory Exercise Challenge
  • ≥ 12% AND ≥ 200 mL < 12% or < 200 mL Challenge Test Flow Variability Fall in FEV1
  • │ │ PC20 ≤ 4 mg/mL Diurnal Var > 15% ≥ 10% to 15%
  • ▼ ▼ │ │ │
  • DIAGNOSIS CONFIRMED Further testing ───────┴────────────────┴────────────────┘
  • (Methacholine/PEF)

Important

Positive Bronchodilator Reversibility Criterion :

An increase in F E V 1 FEV_1 FE V 1 ​ of ≥ 12% AND ≥ 200 mL measured 15 minutes after the inhalation of 200–400 mcg of salbutamol (via pressurized metered-dose inhaler with a spacer) demonstrates significant reversibility, confirming the diagnosis of asthma in adults. In pediatric patients (6–17 years), an increase in F E V 1 FEV_1 FE V 1 ​ of ≥ 12% alone is considered diagnostic.

2. Alternative Objective Diagnostic Modalities

When baseline spirometry is normal or bronchodilator reversibility is equivocal, alternative tests are utilized:

Bronchial Provocation (Methacholine Challenge Test) : The patient inhales escalating concentrations of methacholine, a muscarinic agonist that induces bronchoconstriction in hyperresponsive airways. A provocative concentration causing a 20% decline in F E V 1 FEV_1 FE V 1 ​ ( P C 20 PC_{20} P C 20 ​ ) of ≤ 4.0 mg/mL is highly sensitive and diagnostic for airway hyperresponsiveness; a P C 20 PC_{20} P C 20 ​ between 4.1 and 16 mg/mL is considered borderline; a P C 20 > 16 PC_{20} > 16 P C 20 ​ > 16 mg/mL effectively excludes active asthma.

Peak Expiratory Flow (PEF) Diurnal Variability : The patient records morning and evening PEF before bronchodilator use over 1 to 2 weeks. Diurnal variability calculated as PEF max − PEF min PEF mean × 100 % \frac{\text{PEF}_{\text{max}} - \text{PEF}_{\text{min}}}{\text{PEF}_{\text{mean}}} \times 100\% PEF mean ​ PEF max ​ − PEF min ​ ​ × 100% that exceeds 15% to 20% confirms variable airflow limitation.

Exercise Challenge : A fall in F E V 1 FEV_1 FE V 1 ​ of ≥ 10% to 15% after standardized treadmill or bicycle ergometer exercise supports exercise-induced bronchoconstriction.

Therapeutic Trial of Anti-Inflammatory Therapy : An improvement in F E V 1 FEV_1 FE V 1 ​ of ≥ 12% and ≥ 200 mL (or PEF by > 20%) after 4 to 6 weeks of daily inhaled corticosteroid (ICS) therapy confirms reversible obstruction.

Canadian Thoracic Society (CTS) Criteria for Asthma Control

The fundamental goal of asthma management is to achieve and maintain disease control, minimizing both current impairment (daytime/nighttime symptoms, activity limitation, reliever use) and future risk (exacerbations, accelerated lung function decline, medication adverse effects). The CTS defines asthma control using seven rigorous clinical parameters assessed over the preceding 4 weeks:

  • Assessment Parameter CTS Target for Controlled Asthma Uncontrolled Asthma Characteristic
  • Daytime Symptoms ≤ 2 days per week > 2 days per week
  • Nighttime Symptoms < 1 night per week (mild symptoms) ≥ 1 night per week waking with cough or wheeze
  • Physical Activity Normal (no limitation in exercise or sports) Exercise limitation, avoids stairs or sports
  • Exacerbations Mild and infrequent Moderate to severe, requiring urgent care or oral steroids

Work / School Absenteeism Zero days missed due to asthma symptoms Any missed days of school or occupational work

Fast-Acting Reliever Frequency ≤ 2 doses per week (SABA or PRN budesonide-formoterol; excluding 1 dose/day pre-exercise) > 2 doses per week

Pulmonary Function ( F E V 1 FEV_1 FE V 1 ​ or PEF) ≥ 90% of personal best < 90% of personal best ( F E V 1 < 80 % FEV_1 < 80\% FE V 1 ​ < 80% indicates severe risk)

Sputum Eosinophils (Specialized) < 2% to 3% ≥ 3% eosinophilia (indicates steroid-refractory airway inflammation)

Note

A patient must meet all criteria to be classified as having controlled asthma. The presence of even a single uncontrolled parameter indicates that asthma is uncontrolled and warrants comprehensive reassessment of inhaler technique, adherence, environmental allergen triggers, comorbidities (e.g., allergic rhinitis, GERD, obstructive sleep apnea), and potential pharmacotherapeutic step-up.

CTS 2021 Pharmacotherapy: Matching Treatment to Asthma Severity

Historically, asthma management relied on short-acting beta2-agonists (SABA: salbutamol) for symptom relief. Trials such as SYGMA and PRACTICAL, and large observational datasets, show that relying on SABA without an inhaled corticosteroid (ICS) leaves inflammation untreated and raises the risk of severe exacerbations and asthma death. Dispensing more than 2 SABA inhalers per year is a CTS marker of higher exacerbation risk, and very high yearly use (around 12 canisters) is associated with asthma mortality.

Note

"Track 1 / Track 2" is GINA terminology (Global Initiative for Asthma), not CTS language. Canadian exam items follow the CTS 2021 focused update , which still prefers daily ICS for mild asthma, as summarized below.

CTS category (≥ 12 years) Preferred therapy Alternative or notes

Very mild asthma (well controlled on PRN SABA) PRN SABA may continue if not at higher risk of exacerbation At higher risk (for example, more than 2 SABA inhalers a year or a past severe exacerbation): switch to daily low-dose ICS + PRN SABA, or PRN budesonide-formoterol

Mild asthma (poorly controlled on PRN SABA, or well controlled on low-dose ICS) Daily low-dose ICS + PRN SABA PRN budesonide-formoterol 200/6 mcg instead, when adherence to daily ICS stays poor despite substantial education and support . Daily LTRA is a second-line option

Moderate asthma (not controlled on low-dose ICS) Low-dose ICS/LABA maintenance + PRN SABA, or budesonide-formoterol maintenance-and-reliever therapy (one inhaler for both) Medium-dose ICS; add-on LTRA

Severe asthma Medium/high-dose ICS/LABA ± LAMA (tiotropium); specialist referral Phenotype-directed biologics; lowest effective oral corticosteroid

Children under 12 follow the same principle: daily ICS + PRN SABA is preferred for mild asthma. PRN budesonide-formoterol is not an option under 12.

Using Budesonide-Formoterol as a Reliever

Rationale: formoterol starts working within about 1 to 3 minutes, like salbutamol. Each relief inhalation therefore also delivers a dose of corticosteroid, so the anti-inflammatory dose rises when symptoms rise.

As-needed use (mild asthma, ≥ 12 years): budesonide-formoterol 200/6 mcg, 1 inhalation as needed. The Canadian product limits are up to 6 inhalations on any single occasion and 8 inhalations per day (up to 12 for a short time under medical advice).

Maintenance-and-reliever therapy (moderate to severe): the same inhaler is used for daily maintenance (for example, 1 to 2 inhalations once or twice daily) and as the reliever. A patient using it this way should not also be given salbutamol for routine relief.

Daily ICS with SABA Reliever

A SABA (salbutamol 100 mcg, 1 to 2 puffs PRN) remains an acceptable reliever only alongside daily ICS-containing maintenance therapy in patients with more than very mild asthma.

Before any step-up, check adherence, inhaler technique, triggers, and comorbidities (rhinitis, GERD, obesity, smoking). These explain most apparent treatment failures.

Stepwise Pharmacotherapy & Controller Drug Classes CTS STEPWISE CONTROLLER ESCALATION (≥ 12 YEARS)

  • [Very mild] PRN SABA (low risk) | daily low-dose ICS or PRN bud/form (higher risk)
  • │
  • [Mild] Daily low-dose ICS + PRN SABA (PRN bud/form if daily ICS adherence stays poor)
  • │
  • [Moderate] Low-dose ICS/LABA + PRN SABA OR bud/form maintenance-and-reliever
  • │ (Alternatives: medium-dose ICS, or low-dose ICS + LTRA)
  • │
  • [Severe] Medium-to-high dose ICS/LABA +/- add-on LAMA (tiotropium Respimat)
  • │
  • [Refractory] Specialist care: biologic monoclonal antibody by phenotype
  • 1. Inhaled Corticosteroids (ICS) — Foundational Anti-Inflammatory Therapy

Inhaled corticosteroids represent the cornerstone of chronic asthma pharmacotherapy. By binding to cytosolic glucocorticoid receptors, they translocate to the nucleus to transrepress transcription factors (NF-κB, AP-1), potently suppressing the transcription of pro-inflammatory cytokines, chemokines, adhesion molecules, and inflammatory enzymes (COX-2, iNOS), while restoring beta2-receptor sensitivity.

Inhaled Corticosteroid Low Daily Dose (Adult, mcg) Medium Daily Dose (Adult, mcg) High Daily Dose (Adult, mcg) Clinical Administration Pearls

Ciclesonide ( Alvesco ) 100–200 > 200–400 > 400 Inactive prodrug activated by endogenous esterases in lung tissue; lowest oropharyngeal deposition; once-daily evening dosing.

Fluticasone Propionate ( Flovent ) 100–250 > 250–500 > 500 Negligible oral bioavailability (< 1%) due to extensive hepatic first-pass metabolism by CYP3A4. Available in pMDI and Diskus.

Budesonide ( Pulmicort ) 200–400 > 400–800 > 800 Water soluble; rapidly absorbed from airway mucosa. Available in Turbuhaler and Respules. Foundational partner with formoterol in SMART.

Mometasone Furoate ( Asmanex ) 100–200 > 200–400 > 400 High glucocorticoid receptor affinity; very low systemic bioavailability (< 1%).

Caution

Local Inhaled Corticosteroid Adverse Effects :

The two most frequent local adverse effects of ICS therapy are oropharyngeal candidiasis (oral thrush) and dysphonia (hoarseness) . Pharmacists must counsel patients to use a valved holding chamber (spacer) with pMDIs and to thoroughly rinse the mouth with water and spit it out (gargling and expectorating) immediately after every inhalation.

2. Long-Acting Beta2-Agonists (LABA)

Agents : Formoterol (rapid onset [1–3 min], duration 12 h, full/high intrinsic efficacy), Salmeterol (slower onset [15–30 min], duration 12 h, partial agonist).

Black Box Warning & Clinical Rule : LABAs must NEVER be used as monotherapy in asthma . In the SMART trial and large safety registries, LABA monotherapy without concurrent ICS masked underlying airway inflammation, predisposing patients to fatal bronchospastic episodes. LABAs must always be co-prescribed with an ICS, ideally in a fixed-dose combination inhaler (e.g., budesonide-formoterol [ Symbicort ], fluticasone-salmeterol [ Advair ], fluticasone furoate-vilanterol [ Breo Ellipta ], mometasone-formoterol [ Zenhale ]).

3. Long-Acting Muscarinic Antagonists (LAMA)

Agent : Tiotropium bromide ( Spiriva Respimat 1.25 mcg/actuation; 2 inhalations once daily = 2.5 mcg daily, or 5 mcg daily).

Role : Indicated as an add-on bronchodilator in Step 4 or 5 for patients with persistent airflow obstruction or recurrent exacerbations despite adherence to medium-to-high dose ICS-LABA. It competitively blocks muscarinic M3 receptors on airway smooth muscle, inhibiting acetylcholine-mediated bronchoconstriction and reducing mucus hypersecretion.

4. Leukotriene Receptor Antagonists (LTRA)

Agent : Montelukast ( Singulair 10 mg PO once daily in adults; 5 mg daily in children 6–14 years; 4 mg daily in children 2–5 years; taken in the evening).

Mechanism : High-affinity competitive antagonist of the cysteinyl leukotriene 1 ( C y s L T 1 CysLT_1 C ys L T 1 ​ ) receptor, blocking the actions of L T C 4 LTC_4 L T C 4 ​ , L T D 4 LTD_4 L T D 4 ​ , and L T E 4 LTE_4 L T E 4 ​ . Prevents leukotriene-induced bronchoconstriction, vascular permeability, and mucosal edema.

Clinical Indications : Effective as an add-on therapy in patients with concomitant allergic rhinitis, aspirin-exacerbated respiratory disease (AERD / Samter's triad: asthma, chronic rhinosinusitis with nasal polyps, and severe bronchospasm upon ingestion of aspirin or COX-1 inhibitors), or exercise-induced bronchoconstriction (EIB).

Caution

Montelukast Neuropsychiatric Warning :

The US FDA added a boxed warning in 2020, and Health Canada's product monograph carries warnings about serious neuropsychiatric events with montelukast. Reported adverse events include agitation, aggressive behavior, hostility, depression, severe vivid nightmares, sleep disturbances, hallucinations, and suicidal ideation and behavior . Pharmacists must proactively counsel patients and caregivers to discontinue montelukast immediately and contact their prescriber if any behavioral or mood alterations occur.

5. Biologic Therapies for Severe Refractory Asthma (Step 5)

For patients with severe asthma whose disease remains uncontrolled despite maximal optimized inhaler therapy (high-dose ICS-LABA + LAMA), phenotypic biomarker assessment (blood eosinophil count, total serum IgE, fractional exhaled nitric oxide [FeNO], aeroallergen sensitization) directs targeted monoclonal antibody therapy:

Biologic Agent Target Mechanism Dosing & Route Indication & Biomarker Thresholds

Omalizumab ( Xolair ) Recombinant humanized IgG1k monoclonal antibody that selectively binds circulating free IgE , preventing its binding to high-affinity F c ϵ R I Fc\epsilon RI F cϵ R I receptors on mast cells and basophils. Subcutaneous injection every 2 to 4 weeks; posology determined by baseline serum IgE level and body weight. Severe persistent allergic asthma with documented aeroallergen sensitization, baseline serum IgE 30–700 IU/mL, and frequent exacerbations.

Mepolizumab ( Nucala ) Humanized IgG1k monoclonal antibody that binds directly to interleukin-5 (IL-5) , preventing it from binding to the IL-5 receptor complex on eosinophil cell surfaces. 100 mg subcutaneous injection every 4 weeks. Severe eosinophilic asthma with baseline blood eosinophils ≥ 150 cells/µL (or ≥ 300 cells/µL within the past 12 months).

Benralizumab ( Fasenra ) Humanized afucosylated IgG1k monoclonal antibody targeting the IL-5 receptor alpha ( I L − 5 R α IL-5R\alpha I L − 5 R α ) subunit . Recruits natural killer (NK) cells to induce rapid, direct antibody-dependent cell-mediated cytotoxicity (ADCC), causing near-total depletion of blood and tissue eosinophils within 24 hours. 30 mg subcutaneous injection every 4 weeks for the first 3 doses, then every 8 weeks. Severe eosinophilic asthma with baseline blood eosinophils ≥ 300 cells/µL .

Dupilumab ( Dupixent ) Fully human monoclonal antibody directed against the IL-4 receptor alpha ( I L − 4 R α IL-4R\alpha I L − 4 R α ) subunit , inhibiting shared dual receptor signaling for both IL-4 and IL-13 (key drivers of Type 2 inflammation, goblet cell hyperplasia, and IgE production). 400 mg or 600 mg SC loading dose, followed by 200 mg or 300 mg SC every 2 weeks. Severe eosinophilic asthma or oral corticosteroid-dependent asthma; also indicated for severe atopic dermatitis and chronic rhinosinusitis with nasal polyps.

Acute Asthma Exacerbations: Severity Triage & Emergency Pharmacotherapy

An acute asthma exacerbation is an acute or subacute worsening in symptoms and lung function compared to the patient's baseline, representing a potentially fatal medical emergency. Resuscitation requires immediate objective triage and aggressive pharmacological stabilization.

Clinical Severity Stratification

Mild-to-Moderate Exacerbation : Talks in phrases, prefers sitting to lying, respiratory rate increased, heart rate 100–120 bpm, S a O 2 SaO_2 S a O 2 ​ (on room air) 90%–95%, P E F > 50 % PEF > 50\% PEF > 50% of personal best or predicted.

Severe / Life-Threatening Exacerbation : Talks in single words, hunched forward, agitated or drowsy, respiratory rate > 30 breaths/min, accessory muscle use, suprasternal indrawing, heart rate > 120 bpm (or bradycardia in terminal fatigue), S a O 2 < 90 % SaO_2 < 90\% S a O 2 ​ < 90% , "silent chest" on auscultation (absence of wheezing indicating critical inability to move air), P E F ≤ 50 % PEF \le 50\% PEF ≤ 50% of personal best. ACUTE ASTHMA EXACERBATION RESUSCITATION ALGORITHM

  • Severe Exacerbation: Dyspneic, Accessory Muscle Use, PEF ≤ 50%
  • │
  • ▼
  • IMMEDIATE TRIAGE BUNDLE
  • │
  • ┌───────────────────────┬───────────────┴───────────────┬───────────────────────┐
  • ▼ ▼ ▼ ▼
  • HIGH-DOSE SABA INHALED ANTICHOLINERGIC SYSTEMIC STEROID CONTROLLED OXYGEN
  • Salbutamol 4-8 puffs • Ipratropium bromide • Oral Prednisone • Titrate via nasal
  • pMDI + spacer q20m 4-8 puffs pMDI + spacer 50 mg PO stat prongs to target
  • x 3 doses, OR q20m x 3 doses (with SABA) • Equal efficacy to IV SaO2 93% - 95%
  • 2.5-5 mg nebulized • 500 mcg nebulized • 5-day course • Avoid hyperoxia
  • (no taper needed) in COPD overlap
  • │
  • Re-evaluate Clinical Status at 60 min
  • │
  • ┌────────────────────────┴────────────────────────┐
  • ▼ ▼
  • Good Response (PEF > 70%) Poor Response / Impending Arrest
  • Discharge on 5-day Prednisone • IV Magnesium Sulfate 2 g over 20 min
  • Step up baseline controller • ICU transfer / mechanical ventilation
  • Pharmacotherapeutic Protocols in Acute Exacerbations

Repetitive Inhaled Short-Acting Beta2-Agonists (SABA) :

Salbutamol : Administer 4 to 8 puffs via pMDI with a valved holding chamber every 20 minutes for 3 doses (first hour), then every 1 to 4 hours as needed. Alternatively, administer 2.5 to 5.0 mg via wet nebulization driven by compressed air (or oxygen). Delivering salbutamol via pMDI with a spacer is clinically equivalent or superior in lung deposition to wet nebulization while causing less tachycardia.

Inhaled Anticholinergics (Ipratropium Bromide) :

Dosing : 4 to 8 puffs via pMDI with spacer (or 500 mcg nebulized) combined with salbutamol every 20 minutes for 3 doses in moderate-to-severe exacerbations.

Rationale : Blocks vagally mediated bronchoconstriction. Clinical trials demonstrate that adding ipratropium to salbutamol produces greater bronchodilation, faster improvement in F E V 1 FEV_1 FE V 1 ​ , and a statistically significant reduction in hospital admissions (NNT ≈ 12) compared to salbutamol alone.

Early Systemic Corticosteroids :

Agent & Dose : Prednisone 50 mg orally once daily for 5 days (pediatric dose: 1 mg/kg/day up to a maximum of 50 mg daily for 3 to 5 days). In hospitalized patients unable to swallow, intravenous methylprednisolone (40–80 mg/day in divided doses) is utilized.

Onset & Rationale : Anti-inflammatory effects require 4 to 6 hours to manifest clinically; early administration in the emergency department reduces hospital admission rates and prevents relapse.

Tapering Rule : A 5-day short course of oral prednisone requires no gradual dosage taper ; the hypothalamic-pituitary-adrenal (HPA) axis is not suppressed by courses lasting ≤ 14 days, and abrupt discontinuation does not trigger rebound exacerbations.

Oxygen Therapy :

Administer controlled supplementary oxygen via nasal cannula or simple face mask titrated to maintain an S a O 2 SaO_2 S a O 2 ​ of 93% to 95% (94%–98% in pregnant patients or children). Hyperoxia ( S a O 2 > 98 % SaO_2 > 98\% S a O 2 ​ > 98% ) should be avoided, as it causes reflex vasoconstriction and worsening ventilation-perfusion mismatch.

Intravenous Magnesium Sulfate :

Dose : 2.0 grams IV infused over 20 minutes in adults with severe exacerbations ( F E V 1 < 50 % FEV_1 < 50\% FE V 1 ​ < 50% predicted) that fail to respond to initial inhaled bronchodilators and systemic steroids. Magnesium acts as a physiological calcium antagonist, blocking calcium influx into bronchial smooth muscle cells and triggering potent smooth muscle relaxation.

Clinical Case Vignette: Assessing Control & Regimen Escalation

A 28-year-old female teacher with a 6-year history of asthma presents to your community pharmacy requesting a refill of her salbutamol pMDI. Pharmacy dispensing records reveal she has picked up 4 canisters of salbutamol over the past 5 months. She takes fluticasone propionate 125 mcg pMDI 1 puff BID.

Clinical Assessment:

Patient Interview : She wakes up coughing approximately 2 nights per week. She uses her salbutamol inhaler 4 to 5 days per week (1–2 puffs each time) when climbing stairs at school or during cold weather. She missed 2 days of work last month due to "chest tightness and wheezing."

Inhaler Technique : Demonstrates good pMDI technique without a spacer, but admits she frequently rushes and does not rinse her mouth afterward.

Control Evaluation (CTS Criteria) :

  • Daytime symptoms: 4–5 days/week (uncontrolled; target ≤ 2 days/week)
  • Nighttime awakenings: 2 nights/week (uncontrolled; target < 1 night/week)
  • Reliever frequency: 4–5 times/week (uncontrolled; target ≤ 2 doses/week)
  • Work absenteeism: 2 days missed (uncontrolled; target 0 days missed)

Over-reliance on SABA: 4 canisters in 5 months (~10 canisters/year; dangerously elevated exacerbation risk).

Pharmacotherapeutic Care Plan:

Identify the Safety Gap : The patient has markedly uncontrolled asthma with excessive SABA reliance and inadequate anti-inflammatory coverage.

Therapeutic Escalation Options :

Option A (CTS moderate asthma) : Switch to budesonide-formoterol 200/6 mcg Turbuhaler as maintenance-and-reliever therapy: 1 inhalation BID plus 1 inhalation PRN for symptom relief. Every reliever dose then also delivers corticosteroid, and standalone salbutamol is stopped.

Option B (CTS moderate asthma) : Step up to a low-dose ICS/LABA combination (e.g., fluticasone-salmeterol 100/50 mcg Diskus 1 inhalation BID), keeping salbutamol PRN for relief only.

Either way, first correct technique and adherence, and recheck control in 2 to 3 months.

Counseling & Prevention : Introduce a valved holding chamber for pMDI use (if continuing pMDI), reinforce mouth rinsing after every ICS dose, and provide an updated, written Asthma Action Plan detailing green, yellow (symptom escalation: double ICS or increase SMART inhalations), and red zones (urgent care).